Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Resverlogix Corp RVXCF


Primary Symbol: T.RVX

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

Recent & Breaking News (TSX:RVX)

Resverlogix Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalone in Pulmonary Arterial Hypertension Led by Quebec Heart and Lung Institute – Laval University Researcher

GlobeNewswire March 18, 2019

Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program

GlobeNewswire March 18, 2019

Resverlogix Announces Participation at Prominent Industry and Investor Conferences

GlobeNewswire March 11, 2019

Resverlogix Closes $6.6 Million Private Placement with Shenzhen Hepalink

GlobeNewswire January 31, 2019

Resverlogix Announces Eighth Positive Data Safety Monitoring Board Recommendation For Phase 3 Study of Apabetalone

GlobeNewswire December 19, 2018

Resverlogix Announces Publication on Apabetalone in Atherosclerosis Journal

GlobeNewswire November 28, 2018

Resverlogix Closes $13.5 Million Private Placement

GlobeNewswire November 2, 2018

Resverlogix Announces Participation at Premier Kidney, Alzheimer’s Disease and Cardiovascular Conferences

GlobeNewswire October 22, 2018

Resverlogix Announces Voting Results from the 2018 Annual and Special Meeting of Shareholders

GlobeNewswire September 12, 2018

Resverlogix Presents at Clinical Trials in Alzheimer’s Disease (CTAD) Asia 2018

GlobeNewswire September 4, 2018

Resverlogix Announces $26 Million Private Placement

GlobeNewswire August 30, 2018

Resverlogix Supports Epigenetics Satellite Symposium and Provides Oral Presentation on Apabetalone at the European Society of Cardiology Congress 2018 in Munich

GlobeNewswire August 22, 2018

Resverlogix Announces Seventh Positive Recommendation From The Data Safety Monitoring Board For Phase 3 Study of Apabetalone

GlobeNewswire August 7, 2018

Resverlogix Intends to Pursue U.S. Listing

GlobeNewswire July 31, 2018

Resverlogix Announces Upcoming Presentations at Clinical Trials in Alzheimer’s Disease (CTAD) Asia and Alzheimer’s Association International Conference (AAIC)

GlobeNewswire July 17, 2018

Hemostemix Formalizes World-Class Scientific Advisory Board

GlobeNewswire July 5, 2018

Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone

GlobeNewswire June 14, 2018

Resverlogix Announces Withdrawal of Public Offering of Units

GlobeNewswire June 8, 2018

Resverlogix Highlights Potential to Develop Apabetalone as a Therapeutic for HIV-1 Eradication Utilizing the “Shock and Kill” Approach

GlobeNewswire June 7, 2018

Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress

GlobeNewswire May 24, 2018